Tags

Type your tag names separated by a space and hit enter

Lithium and Therapeutic Targeting of GSK-3.
Cells. 2021 01 28; 10(2)C

Abstract

Lithium salts have been in the therapeutic toolbox for better or worse since the 19th century, with purported benefit in gout, hangover, insomnia, and early suggestions that lithium improved psychiatric disorders. However, the remarkable effects of lithium reported by John Cade and subsequently by Mogens Schou revolutionized the treatment of bipolar disorder. The known molecular targets of lithium are surprisingly few and include the signaling kinase glycogen synthase kinase-3 (GSK-3), a group of structurally related phosphomonoesterases that includes inositol monophosphatases, and phosphoglucomutase. Here we present a brief history of the therapeutic uses of lithium and then focus on GSK-3 as a therapeutic target in diverse diseases, including bipolar disorder, cancer, and coronavirus infections.

Links

PMC Free PDF

Authors+Show Affiliations

Snitow ME
Department of Medicine, Perelman School of Medicine, University of Pennsylvania, 3400 Spruce St., Philadelphia, PA 19104, USA.
Bhansali RS
Department of Medicine, Perelman School of Medicine, University of Pennsylvania, 3400 Spruce St., Philadelphia, PA 19104, USA.
Klein PS
Department of Medicine, Perelman School of Medicine, University of Pennsylvania, 3400 Spruce St., Philadelphia, PA 19104, USA.

MeSH

AnimalsAntimanic AgentsBipolar DisorderCoronavirusGlycogen Synthase Kinase 3HumansLithium CompoundsNeoplasmsNeurodegenerative DiseasesPhosphoric Monoester HydrolasesSevere Acute Respiratory SyndromeSignal Transduction

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

33525562

Citation

Snitow, Melinda E., et al. "Lithium and Therapeutic Targeting of GSK-3." Cells, vol. 10, no. 2, 2021.
Snitow ME, Bhansali RS, Klein PS. Lithium and Therapeutic Targeting of GSK-3. Cells. 2021;10(2).
Snitow, M. E., Bhansali, R. S., & Klein, P. S. (2021). Lithium and Therapeutic Targeting of GSK-3. Cells, 10(2). https://doi.org/10.3390/cells10020255
Snitow ME, Bhansali RS, Klein PS. Lithium and Therapeutic Targeting of GSK-3. Cells. 2021 01 28;10(2) PubMed PMID: 33525562.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Lithium and Therapeutic Targeting of GSK-3. AU - Snitow,Melinda E, AU - Bhansali,Rahul S, AU - Klein,Peter S, Y1 - 2021/01/28/ PY - 2021/01/05/received PY - 2021/01/24/revised PY - 2021/01/25/accepted PY - 2021/2/2/entrez PY - 2021/2/3/pubmed PY - 2021/2/11/medline KW - GSK-3 KW - Wnt KW - bipolar disorder KW - cancer KW - coronavirus KW - lithium KW - nucleocapsid KW - severe acute respiratory syndrome (SARS) JF - Cells JO - Cells VL - 10 IS - 2 N2 - Lithium salts have been in the therapeutic toolbox for better or worse since the 19th century, with purported benefit in gout, hangover, insomnia, and early suggestions that lithium improved psychiatric disorders. However, the remarkable effects of lithium reported by John Cade and subsequently by Mogens Schou revolutionized the treatment of bipolar disorder. The known molecular targets of lithium are surprisingly few and include the signaling kinase glycogen synthase kinase-3 (GSK-3), a group of structurally related phosphomonoesterases that includes inositol monophosphatases, and phosphoglucomutase. Here we present a brief history of the therapeutic uses of lithium and then focus on GSK-3 as a therapeutic target in diverse diseases, including bipolar disorder, cancer, and coronavirus infections. SN - 2073-4409 UR - https://www.unboundmedicine.com/medline/citation/33525562/Lithium_and_Therapeutic_Targeting_of_GSK_3_ DB - PRIME DP - Unbound Medicine ER -